In a report released on January 2, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $83.00. The company’s shares closed yesterday at $51.93.
Miksic covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Edwards Lifesciences, and Globus Medical. According to TipRanks, Miksic has an average return of 6.2% and a 60.66% success rate on recommended stocks.
In addition to Barclays, Globus Medical also received a Buy from Stifel Nicolaus’s Mathew Blackman in a report issued on December 28. However, on January 1, BTIG maintained a Hold rating on Globus Medical (NYSE: GMED).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $80.04 and a one-year low of $43.39. Currently, Globus Medical has an average volume of 1.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical (GMED) Company Description:
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Read More on GMED:
- Globus Medical price target raised to $58 from $53 at Truist
- Globus Medical price target raised to $71 from $67 at Canaccord
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
- Globus Medical price target lowered to $53 from $58 at Truist
- Globus Medical backs FY23 EPS view $2.30, consensus $2.32
